Short answer
Upstream Bio, Inc. (UPB) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $683,000 (down 61.1% year over year) with net income of −$34M.
Q3 2025 key financials · XBRL
- Revenue
- $683,000
- −61.1% YoY · −27.1% QoQ
- Net income
- −$34M
- +18.8% YoY · +15.6% QoQ
- Operating margin
- -5539.4%
- EPS (diluted)
- −$0.63
- +96.5% YoY · +14.9% QoQ
Source: XBRL data from the Upstream Bio, Inc. (UPB) Q3 2025 10-Q on SEC EDGAR. USD.
Upstream Bio, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Financial risk: $372.4 million cash, equivalents and short-term investments funding operations through 2027 under current assumptions
- Financial risk: Net loss $101.0 million for nine months ended September 30, 2025 versus $41.6 million in 2024
- Operational risk: Verekitug remains the company’s only product candidate and is still in clinical development
- Regulatory risk: FDA may reject foreign clinical-trial data, requiring costly additional trials and delaying commercialization
- Compliance risk: Post-approval products require continuing cGMP and GCP compliance, safety reporting and registration-controls
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.